替吉奥联合吉西他滨治疗晚期胰腺癌 35例观察

薛丽英

文章摘要

薛丽英.替吉奥联合吉西他滨治疗晚期胰腺癌 35例观察[J].安徽医药,2022,26(1):188-191.

替吉奥联合吉西他滨治疗晚期胰腺癌 35例观察

Tegafur combined with gemcitabine in the treatment of advanced pancreatic cancer: a report of 35 cases

DOI：10.3969/j.issn.1009-6469.2022.01.044

中文关键词: 胰腺肿瘤替吉奥吉西他滨客观缓解率糖抗原 242 糖抗原 199 癌胚抗原卡氏功能状态量表评分

英文关键词: Pancreatic neoplasms Tegafur Gemcitabine Objective response rate Carbohydrate antigen 242 Carbohy-drate antigen 199 Carcinoembryonic antigen Karnofsky performance status score

基金项目:

作者	单位
薛丽英	内蒙古自治区人民医院肿瘤内科，内蒙古自治区呼和浩特 010010

摘要点击次数: 1187

全文下载次数: 380

中文摘要:

目的探究替吉奥联合吉西他滨对晚期胰腺癌病人客观缓解率(ORR)、血清糖抗原 242(CA242)、糖抗原 199(CA199)及癌胚抗原( CEA)水平及卡氏功能状态量表( KPS)评分的影响。方法选取内蒙古自治区人民医院 2017年 3月至 2018年 9月收治的晚期胰腺癌病人 70例，按照随机数字表法分为研究组和对照组各 35例。研究组给予替吉奥 +吉西他滨联合治疗，对照组给予单一药物吉西他滨治疗。观察两组治疗后 ORR及治疗前后血清 CA242、CA199、CEA水平、 KPS评分变化，并对比两组治疗方案安全性及治疗后 1年生存情况。结果研究组病人治疗后 ORR和临床控制率( DCR)分别为 42.86%(15/35)、 82.86%(29/35)，均明显高于对照组 20.00%(7/35)、 60.00%(21/35)，两组比较差异有统计学意义( P<0.05)；治疗后，两组病人血清 CA242、CA199及 CEA水平均比治疗前显著降低，且研究组血清 CA242、CA199及 CEA水平［( 26.34±8.54)U/mL、(87.62± 25.67)U/mL、(7.23±2.11)μg/L］明显低于对照组［( 40.63±12.21)U/mL、(126.24±32.33)U/mL、(14.12±3.67)μg/L］(P<0.05)；治疗后，研究组病人 KPS评分均比治疗前明显升高，且治疗后研究组 KPS评分( 85.52±14.44)分显著高于对照组( 78.45±12.88)分( P <0.05)。结论替吉奥联合吉西他滨一线治疗晚期胰腺癌临床有效率及控制率都高于单一吉西他滨治疗，且在保证安全情况下，还可尽快纠正血清 CA242、CA199及 CEA水平，提高病人生活质量。

英文摘要:

Objective To investigate the effects of tegafur combined with gemcitabine on the objective response rate (ORR), serumcarbohydrate antigen 242 (CA242), carbohydrate antigen 199 (CA199), carcinoembryonic antigen (CEA) level and Karnofsky perfor-mance status (KPS) score in patients with advanced pancreatic cancer.Methods A total of 70 patients with advanced pancreatic can-cer admitted to the Inner Mongolia Autonomous Region People's Hospital from March 2017 to September 2018 were selected as the re-search objects. They were randomly divided into study group and control group, with 35 cases in each group. The patients in the studygroup were treated with tegafur + gemcitabine, while the patients in the control group were treated with gemcitabine alone. The ORR af-ter treatment and changes of serum CA242, CA199, CEA level and KPS score before and after treatment were observed, and the safetyof treatment plan and 1-year survival of the two groups were compared.Results The ORR and the disease control rate (DCR) of thestudy group were 42.86% (15/35) and 82.86% (29/35), respectively, which were significantly higher than 20.00% (7/35) and 60.00%(21/35) of the control group, and the differences between the two groups were statistically significant (P < 0.05); after treatment, the se-rum CA242, CA199 and CEA level of the two groups weresignificantly lower than those before treatment, and the serum CA242, CA199and CEA level of the study group [(26.34±8.54)U/mL, (87.62±25.67)U/mL, (7.23±2.11)μg/L] were significantly lower than those of thecontrol group [(40.63±12.21)U/mL, (126.24±32.33)U/mL, (14.12±3.67)μg/L] (P<0.05); after treatment, KPS scores of the study groupwas significantly higher than before treatment, and KPS score of the study group (85.52±14.44) score was significantly higher than thatof the control group (78.45±12.88) score (P<0.05).Conclusions The clinical effective rate and control rate of tegafur combined withgemcitabine in the treatment of advanced pancreatic cancer are higher than those of single gemcitabine treatment, and under the condi-tion of safety, it can also adjust the serum CA242, CA199 and CEA levels as soon as possible and improve the quality of life of patients.

查看全文查看/发表评论下载PDF阅读器

关闭